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Background: The study was designed to evaluate the safety and
efficacy of exisulind, a selective apoptotic antineoplastic drug, in
combination with gemcitabine as second-line therapy in patients
with progressing advanced non–small cell lung cancer.
Methods: Patients whose disease progressed more than 3 months
from completion of first-line chemotherapy were eligible for this
phase I/II trial. Primary end points were maximally tolerated dose
and time to progression. Patients in the phase I portion of the study
were treated with gemcitabine (1250 mg/m2) in combination with
three escalated dose levels of exisulind. Treatment involved six
cycles of gemcitabine and exisulind followed by exisulind mainte-
nance. The study was subsequently expanded to phase II.
Results: Thirty-nine patients (15 in phase I and 24 in phase II) were
treated. The regimen was well tolerated with grade 3 fatigue and
grade 3 constipation being dose-limiting toxicities. The maximally
tolerated dose was not reached. Dose level 3 of exisulind (250 mg
twice daily) in combination with gemcitabine was used for phase II.
The overall response rates were 7% (phase I), 17% (phase II), and
13% (all). Median time to progression and median and 1-year
survival, respectively, were 3.7 and 9.7 months and 33% (phase I);
4.3 and 9.4 months and 41% (phase II); and 4.1 and 9.4 months and
39% (all).
Conclusion: Although the study met its primary end point of
improving time to progression (more than 4.1 months in phase II),
we did not observe a clear survival advantage and thus do not plan
to further investigate this schedule of gemcitabine and exisulind.
Key Words: Gemcitabine, Exisulind, Second-line therapy, Pro-
gressing non–small cell lung cancer.
(J Thorac Oncol. 2006;1: 218–225)
Chemotherapy has been the mainstay of treatment forpatients with advanced non–small cell lung cancer
(NSCLC). Although 19 to 32% of chemo-naive patients will
respond to first-line standard cytotoxic doublets,1–3 virtually
all eventually face disease progression requiring further ther-
apy. For such patients, docetaxel and pemetrexed are the only
two cytotoxic drugs approved for use as second-line mono-
therapy, with dismal response rates of 6 to 9% and median
survival of 6-8 months.4–6 Therefore, more active regimens
are clearly needed. In response to the need for effective
therapies for patients with recurrent or refractory NSCLC,
researchers have extensively investigated cytotoxic as well as
molecularly targeted agents. Different agents with different
targets, schedules, and regimens have been studied.
Gemcitabine (Lilly, Indianapolis, IN), an antimetabo-
lite analogue of cytosine arabinoside, has significant clinical
activity in several human tumors. The combination of gem-
citabine and a platin is among standard first-line regimens for
NSCLC in North America and other countries. A large phase
III randomized trial conducted by the Eastern Cooperative
Oncology Group has demonstrated that the combination of
gemcitabine and cisplatin is at least as active as other new
platinum-based regimens in chemo-naive patients with
NSCLC.1 In addition, a meta-analysis showed a statistically
significant improvement in progression-free survival of gem-
citabine-platinum regimens compared with other regimens
containing a third-generation agent and platinum.7
Exisulind (sulindac sulfone) (OSI Pharmaceuticals,
Melville, NY), a selective apoptotic antineoplastic drug, is an
inhibitor of the enzyme cyclic GMP phosphodiesterase. By
increasing cyclic GMP, exisulind activates protein kinase G
and JNK1 pathway, thus inducing apoptosis of tumor cells.8,9
The apoptotic and growth inhibition activity of exisulind has
been demonstrated in various tumor cell lines, including lung
cancer.8,10–13 The combination of exisulind or its potent
analog OSI-461 (previously known as CP-461) with cyto-
toxic drugs such as gemcitabine, vinorelbine, and irinotecan
enhanced the inhibition of human lung cancer cell growth in
culture.14,15 In orthotopic lung cancer model systems, exisu-
lind combined with docetaxel significantly increased apopto-
sis, inhibited tumor growth and metastasis, and prolonged
survival.11,16
*Ohio State University College of Medicine and Comprehensive Cancer
Center, Columbus, Ohio, †University University of Wisconsin Medical
School and Comprehensive Cancer Center, Madison, Wisconsin, ‡Wis-
consin Oncology Network
Address correspondence to: Joan H. Schiller, MD, University of Wisconsin
Comprehensive Cancer Center, 600 Highland Ave. K4/548, Madison, WI
53792. E-mail: jhschill@wisc.edu
Copyright © 2006 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/06/0103-0218
Journal of Thoracic Oncology • Volume 1, Number 3, March 2006218
Based on preclinical data, we hypothesized that the
combination of gemcitabine and exisulind would improve the
response rate and survival in patients with NSCLC with
disease progression after first-line chemotherapy. In this
phase I/II study, we examined the safety and antitumor
activity of this combination as second-line treatment in this
patient population.
PATIENTS AND METHODS
Eligibility Criteria
The eligibility criteria for this study included: histolog-
ically confirmed NSCLC, disease progressing more than 3
months from completion of first-line chemotherapy; having
undergone only one previous chemotherapy regimen for ad-
vanced disease; measurable or evaluable disease; an Eastern
Cooperative Oncology Group performance status of 0 to 1;
adequate bone marrow function (white cell count 4000/mm3,
neutrophils 1500/mm3, and platelets 100,000/mm3); liver
function (bilirubin less than or equal to the upper limit of normal
and transaminases 2.5 times the upper limit of normal); and
kidney function (creatinine 1.5 mg/dl or creatinine clearance
60 ml/min). Patients had not undergone radiotherapy for at
least 4 weeks. Patients with clinically stable brain metastases
were eligible. Other than ibuprofen and naproxen, non-steroidal
anti-inflammatory drugs, COX-2 inhibitors, salicylates, and su-
lindac were not allowed during the study. Patients who previ-
ously received gemcitabine were ineligible.
Treatment Plan
The study consisted of two steps: phase I (step 1) to
assess safety and to determine the maximally tolerated dose
(MTD) and phase II (step 2) to evaluate the efficacy of the
study regimen. Phase I portion involved three dose levels of
exisulind (125 mg twice daily, 125 mg in the morning/250
mg in the evening, and 250 mg twice daily) given orally
every day in combination with gemcitabine 1250 mg/m2
given as a 30-minute intravenous infusion on day 1 and 8 of
a 3-week cycle. Three patients were entered in each dose
level in a traditional phase I dose-escalation design. Dose
escalation was planned as followed: (1) If dose-limiting
toxicity (DLT) occurs in two of the three patients at dose
level 1 during cycle 1, we will conclude that the drug
combination is too toxic and stop. (2) If DLT occurs in one of
the three patients, an additional three patients will be added to
further quantify the toxicity at that dose level. (3) Dose
escalation will continue until DLT occurs in at least two of
six patients. (4) MTD is the dose level preceding DLT in two
of six patients, or dose level 3 if zero of three or one of six
patients experiences DLT at that dose level. MTD is the
chosen dose for step 2.
Toxicity evaluation was based on the National Cancer
Institute Common Toxicity Criteria (version 2). DLTs were
defined as grade 4 neutropenia for 7 days; grade 4 neutro-
penia accompanied by a fever (single elevation in oral tem-
perature to 38.5°C, or three elevations to 38°C during a
24-hour period) that requires parenteral antibiotics; grade 4
thrombocytopenia; delay in gemcitabine and/or exisulind
administration of more than 2 weeks; or other grade 3 or 4
non-hematological treatment-related toxicities.
Patients were examined and evaluated before each
treatment cycle. To assess tumor response, computed tomo-
graphic scans were obtained, and tumors were measured after
every two cycles of treatment. Response Evaluation Criteria
in Solid Tumors criteria were used for tumor evaluation.17
Patients with complete response (CR), partial response (PR),
or stable disease (SD) continued on treatment for a total of six
cycles of chemotherapy or until progressive disease (PD) or
unacceptable toxicities developed. Patients with CR, PR, or
SD after completing six cycles of chemotherapy were al-
lowed to continue on exisulind maintenance. Patients with
PD or unacceptable toxicities at any time were discontinued
from protocol treatment.
Statistical Considerations
The primary end points of this study were to determine
the MTD of exisulind in combination with gemcitabine and to
evaluate time to progression (TTP) in patients with advanced
NSCLC after failure of first-line chemotherapy. The second-
ary end point was to assess response rate and overall survival.
Using standard approximations based on an exponential dis-
tribution for time to event and assuming that patient accrual
was uniform over time, it was estimated that an observation
of 18 disease progressions in step 2 was needed. This sample
size provided 95% power to detect a 50% increase in median
TTP from 3 months for historical control18,19 to 4.5 months
on the protocol therapy with gemcitabine and exisulind ac-
cording a one-sided log rank test with the 0.1 level of
significance. The rationale was that we were not so much
concerned about falsely claiming efficacy of the new therapy,
but we did not want to miss a promising therapy because of
a small power. We planned to accrue a total of 24 patients
with an additional follow-up after the last patient was en-
rolled until there was a total of 18 disease progressions for
step 2 of the protocol.
According to this design (sample size estimation), the
second-line therapy with gemcitabine and exisulind would be
considered for further testing if the observed median TTP was
4.1 months, which corresponds to the 90% lower confi-
dence limit for the true median TTP with the protocol therapy
when 18 disease progressions were observed in the study.
Data were analyzed on an intent-to-treat basis. Time to
event data such as TTP and overall survival were analyzed
using the Kaplan-Meier method, separately for each step and
also combined. TTP and survival were determined from the
date of enrollment to the date of progression and of death,
respectively. The objective response rate and qualitative and
quantitative toxicities were summarized with descriptive sta-
tistics.
RESULTS
A total of 39 patients were enrolled in the study
between April 2001 and April 2004. There were 15 patients
in step 1 (phase I) and 24 patients in step 2 (phase II).
Treatment was discontinued early during cycle 1 of therapy in
one patient in step 1 because of grade 3 fatigue (DLT). One
patient in step 2 was found ineligible during the course of
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therapy (disease recurring 3 months from last chemother-
apy). That patient received six cycles of treatment with SD as
the best response. All 39 patients were evaluated for toxici-
ties. Treatment efficacy was assessed in 24 phase II patients.
We also obtained data on response and survival in 15 phase
I patients. After a median follow-up of 22 months (range,
12–47 months), 33 of 39 patients (85%) had died.
Table 1 shows the clinical characteristics of all 39
patients. Median age was 65 years. Most patients were male
(72%), had PS of 1 (72%), and distant metastatic disease
(67%). There was a greater proportion of patients with met-
astatic disease enrolled in phase II than in phase I (75%
versus 53%). Of the patients, 18% had lobectomy or pneu-
monectomy as the initial therapy, and two of three received
radiation to the chest or metastatic sites. All but one were
treated with first-line platinum-based chemotherapy, of which
carboplatin/paclitaxel was the most common regimen.
Phase I Results
Of the 15 patients who entered the phase I portion, six
were treated with dose level 1, three with dose level 2, and six
with dose level 3. Overall, patients tolerated treatment well,
with only one DLT (grade 3 fatigue) occurring in dose level
1 and one DLT (grade 3 constipation) in dose level 3 (Table
2). Grade 3 and 4 neutropenia identified in 27% and 20%
patients, respectively, were the most common toxic events.
Only one patient (7%) in phase I developed febrile neutro-
penia. The MTD was not reached. Gemcitabine 1250 mg/m2
on day 1 and exisulind 250 mg twice daily (dose level 3) were
chosen for the subsequent phase II portion.
Efficacy
The overall response rate (PR) was 13% for all 39
patients. Of the patients, 7% achieved PR in phase I and 17%
in phase II (Table 3). Approximately half the patients in both
steps (21 patients) had stable disease as the best response at
the first imaging tumor evaluation, of whom 52% (11 pa-
tients) completed six cycles of chemotherapy and 33% (seven
patients) went on to receive exisulind maintenance. Median
TTP and median and 1-year survival for 24 patients in phase
II was 4.3 and 9.4 months and 41%, respectively (Table 3).
The result for the 15 patients in phase I was 3.7 and 9.7
months and 33%, respectively. Observed differences in TTP
and survival between the two groups were not statistically
significant. TTP and overall survival for all 39 patients are
presented in Table 3 and Figures 1 and 2.
TABLE 1. Patient Characteristics
Characteristic Phase I (n  15) Phase II (n  24) Total (n  39)
Age (years)
Median 66 65 65
Range 56–77 39–77 39–77
Sex
Male 9 (60%) 19 (79%) 28 (72%)
Female 6 (40%) 5 (21%) 11 (28%)
ECOG performance status
0 5 (33%) 6 (25%) 11 (28%)
1 10 (67%) 18 (75%) 28 (72%)
Histology
Adenocarcinoma 7 (47%) 11 (46%) 18 (46%)
Squamous cell carcinoma 2 (13%) 7 (29%) 9 (23%)
Large cell carcinoma 3 (20%) 1 (4%) 4 (10%)
Mixed or non-specified NSCLC 3 (20%) 5 (21%) 8 (21%)
Disease status
Localized advanced 7 (47%) 6 (25%) 13 (33%)
Distant metastatic 8 (53%) 18 (75%) 26 (67%)
Metastatic sites
Bone 1 (7%) 5 (21%) 6 (15%)
Liver 1 (7%) 5 (21%) 6 (15%)
Brain 2 (13%) – 2 (5%)
Pleura 4 (27%) 5 (21%) 9 (23%)
Adrenal gland – 3 (13%) 3 (8%)
Prior chemotherapy
Paclitaxel/carboplatin 12 (80%) 21 (88%) 33 (85%)
Other platin-based combination 3 (20%) 2 (8%) 5 (13%)
Vinorelbine – 1 (4%) 1 (2%)
Prior radiation therapya 11 (73%) 15 (63%) 26 (67%)
Prior lung resection – 7 (29%) 7 (18%)
ECOG, Eastern Cooperative Oncology Group; NSCLC, non–small-cell lung cancer.
aIncluding radiation to the primary lung tumor or metastatic lesions.
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Toxicities
Treatment-related toxicities are shown in Table 2. Cy-
topenias were the most common adverse events. Although
almost half the patients in phase I and II had grade 3 or 4
granulocytopenia, only 15% had an absolute neutrophil count
of less than 500/mm3, 3% (one patient) developed febrile
neutropenia, and 3% had grade 3 neutropenic infection. No
grade 4 anemia or thrombocytopenia was observed; only 11%
and 8% of patients, respectively, developed these two events
at grade 3. Besides cytopenias, grade 3 fatigue was the only
adverse event seen in more than 10% of patients (four
patients). Whereas bone marrow suppression was attributed
to gemcitabine, elevation of liver function tests (mainly
transaminases) was probably related to exisulind. Grade 3
increase in AST and/or ALT was observed only in the phase
II portion (13%). One patient (7%) in phase I and four
patients (17%) in phase II were removed from the study
because of abnormal liver function. This adverse event was
reversible after exisulind was withheld.
DISCUSSION
Gemcitabine in combination with a platin is one of the
most active regimens for chemo-naive patients with NSCLC. To
identify the role of gemcitabine in second-line therapy, several
trials have been conducted in previously treated patients (Table
4). In those trials, gemcitabine was given either as single agent
or in combination with another drug. A response rate of 14 to
21% has been reported in various phase II trials using single-
agent gemcitabine, with median and 1-year survival in the range
of 5.1 to 7.9 months and 29 to 45%, respectively.19–22 In a recent
phase II trial conducted by the California Cancer Consortium
among 61 patients with sensitive or refractory advanced disease
(defined as progression more than or less than 6 months after
completing platinum-based therapy), gemcitabine resulted in an
median TTP of 4.1 months and median survival of 8.6 months,
despite a low response rate of 7%.23 Median TTP and survival
were 5.4 and 11.9 months, respectively, in chemo-sensitive
patients versus 3.1 and 7.1 months, respectively, in chemo-
refractory patients.
TABLE 3. Adverse Events
Toxic events Phase I (n  15) Phase II (n  24) Total (n  39)
Hematologic
Absolute neutrophil count
Grade 3 4 (27%) 8 (33%) 12 (31%)
Grade 4 3 (20%) 3 (13%) 6 (15%)
Anemia—grade 3 1 (7%) 3 (13%) 4 (10%)
Platelet count—grade 3 – 3 (13%) 3 (8%)
Febrile neutropenia—grade 3 1 (7%) – 1 (3%)
Infection with neutropenia—grade 3 – 1 (4%) 1 (3%)
Nonhematologic
AST and/or ALT
Grade 3 – 3 (13%) 3 (8%)
Grade 2 3 (20%) 5 (21%) 8 (21%)
Vomiting—grade 3 1 (7%) – 1 (3%)
Anorexia—grade 3 – 1 (4%) 1 (3%)
Constipation—grade 3 1 (7%)a 1 (4%) 2 (5%)
Fatigue—grade 3 1 (7%)a 3 (13%) 4 (10%)
AST, aspartate transaminase; ALT, alanine aminotransferase.
aDose-limiting toxicities.
TABLE 2. Patient Outcome
Variable Phase I (n  15) Phase II (n  24) Total (n  39)
Best response
Partial response 1 (7%) 4 (17%) 5 (13%)
Stable disease 8 (53%) 13 (54%) 21 (54%)
Progressive disease 5 (33%) 7 (29%) 12 (31%)
Not determined 1 (7%)a – 1 (2%)
Median time to progression (95% CI) (months) 3.7 (1.6, ) 4.3 (3.1, 7.8) 4.1 (2.7, 6.6)
Survival
Median (95% CI) (months) 9.7 (6.5, 20.7) 9.4 (7.7, ) 9.4 (7.1, 15.0)
One-year (95% CI) (%) 33 (16, 68) 41 (26, 67) 39 (26, 57)
aEarly withdrawal because of toxicities.
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As shown in Table 4, gemcitabine has also been tested
in combination with other cytotoxic agents (docetaxel,24–27
paclitaxel,28,29 vinorelbine,30–32 and irinitecan33) in several
phase II trials in previously treated patients. Although the
response rate was reported as high as 12 to 33%, survival
results vary significantly. The inconsistent results and poten-
tial toxicities may limit the application of combined cytotoxic
regimens in this patient population.
One of the most promising advances in cancer therapy
is the development of molecularly targeted agents. The ty-
rosine kinase inhibitor erlotinib, recently approved for use in
previously treated patients with NSCLC,34 and promising
results of the anti-VEGF monoclonal antibody bevacizumab
in combination with chemotherapy in chemo-naive patients35
are among the most encouraging examples of molecularly
targeted therapy. Exisulind, or sulindac sulfone, is a novel
FIGURE 1. Time to progression (n  39).
FIGURE 2. Overall survival (n  39).
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apoptotic antineoplastic drug that selectively inhibits cyclic
GMP phosphodiesterase, leading to tumor cell apoptosis.
Early clinical trials involving exisulind with or without cy-
totoxic chemotherapy have been conducted. In a phase I trial
examining the tolerability and safety of exisulind as a che-
mopreventive agent in patients with familial adenomatous
polyposis, exisulind was found to be generally well tolerated,
with reversible hepatic dysfunction being the DLT.36 The
MTD of exisulind in this patient population, which had
undergone subtotal colectomy, was 300 mg twice daily. In a
phase I study of exisulind in 15 previously treated patients
with lung cancer, the MTD was 500 mg/day with DLT due to
gastrointestinal symptoms and liver dysfunction.37 Although
no response was observed, prolonged SD (14 to 15 weeks)
was reported in two patients. Other early studies investigated
the combination of exisulind with single-agent docetaxel,38
vinorelbine,39 or capecitabine,40 or with chemotherapy dou-
blets41,42 in patients with advanced cancers.
In this phase I/II trial, we hoped to improve the antitu-
mor activity of second-line gemcitabine in patients with
recurrent NSCLC by adding the novel apoptotic drug exisu-
lind. These patients are seen more and more frequently in
daily practice: patients who still have a good performance
status after failure of front-line platinum-based doublets and
thus merit further systemic treatment. In addition to requiring
good performance status, we electively enrolled the so-called
“sensitive” patients whose disease progressed more than 3
months since the end of their first-line therapy. These patients
were thought to have a better prognosis than those whose
disease progresses during or shortly after front-line chemo-
therapy, and they therefore represent the group of patients
most likely to respond. Overall, the combination was well
tolerated with myelotoxicity as the main adverse event. Of
non-hematological toxicities, increase in transaminases
seemed to be related to exisulind. However, this event was
limited to grade 3 or less and was reversible.
In terms of antitumor activity, the combination of
gemcitabine and exisulind resulted in an overall response rate
of 13% in this phase I/II trial. Median TTP and median and
1-year survival of patients in phase II was 4.3 and 9.4 months
and 41%, respectively. For all 39 patients, the result was 4.1
and 9.4 months and 39%. Overall, the survival outcome of
patients treated with gemcitabine and exisulind in this study
seems only slightly better or comparable with other phase II
studies of single-agent gemcitabine (Table 4), particularly as
our patients were highly selected (patients with sensitive
TABLE 4. Second-Line Therapies for Advanced NSCLC
Second-line regimens Phase Patient (n) RR (%) TTP (mo) MS (mo) 1 yr S (%)
Docetaxel
Shepherd et al.4 III 55a,b 6 2.5 7.5 37
Fossella et al.5 III 120a,b 7 2 5.7 32
Hanna et al.6 III 276 9 3.5 7.9 30
Pemetrexed (Hanna et al.6) III 265 9 3.4 8.3 30
Erlotinib (Shepherd 2004) 4 III 488b 9 2.2 6.7 31
Gemcitabine monotherapy
Gridelli et al.19 II 30 20 2.3 5.1 –
Crino et al.20 II 83b 19 – 7.9 45
Van Kooten et al.21 II 29b 21 3 5.5 29
Van Putten et al.22 II 29 14 – 5.1 –
Lara et al.23 II 61b 7 4.1 8.6 –
Gemcitabine (G)-combined regimens
G  docetaxel (Hainsworth et al.24) II 40 10 – 6 20
G  docetaxel (Kosmas et al.25) II 43 33 6 8.5 30
G  docetaxel (Kakolyris et al.26) II 32b 16 – 6.5 28
G  docetaxel (Niho et al.27) II 29 28 4.2 11.1 41
G  paclitaxel (Kakolyris et al.28) II 49 18 – 10.3 –
G  paclitaxel (Dongiovanni et al.29) II 34 12 2.8 6.5 23
G  vinorelbine (Hainsworth et al.30) II 50 18 – 6.5 20
G  vinorelbine (Kosmas et al.31) II 40 23 4.5 7 17
G  vinorelbine (Herbst et al.32) II 36b 17 4.6 8.5 30
G  irinotecan (Georgoulias et al.33) II 76 18 7.5 9 25
Exisulind (E)-combined regimens
E  Docetaxel (OSI43) IIIc – 9 3 6.9 31
E  Gemcitabine (Hoang, 2005) I/II 39d 13 4.1 9.4 39
RR, response rate; TTP, time to progression; MS, median survival; 1 Y S, 1-year survival.
aDocetaxel 75 mg/m2 arm.
bIncluding patients who had received one or more prior chemotherapy regimens.
cDid not improve survival compared with docetaxel plus placebo control.
dOnly patients with “sensitive” disease were enrolled.
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disease) for the trial. The combination of gemcitabine and
exisulind resulted in no clear advantage compared with phase
III studies of single-agent docetaxel or pemetrexed. Further-
more, in a randomized phase III study investigating docetaxel
with or without exisulind in previously treated patients with
NSCLC, the combination of docetaxel and exisulind did not
improve median (6.9 months in both arms), 1-year (31%
versus 30%), or progression-free survival (3 versus 2.8
months).43
Although the study met its primary end point of im-
proving TTP (4.1 months in phase II), we did not observe
a clear overall survival advantage compared with other stud-
ies. The possible explanations are (1) there is no interaction
between exisulind and cytotoxic drugs (despite preclinical
observations), (2) suboptimal dosing of exisulind, or (3)
suboptimal scheduling. Nevertheless, because of the disap-
pointing results from the phase III trial of concurrent do-
cetaxel and exisulind discussed above, we do not plan to
further study this schedule of gemcitabine and exisulind.
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